INTRODUCTION

As pointed out by the WHO in the Global Tuberculosis (TB) Report 2012, China is heavily burdened with TB. Pulmonary tuberculosis (PTB)
is a chronic infectious respiratory disease caused by the bacterium *Mycobacterium tuberculosis* (*M. tb*) and primarily affecting the lungs. If an individual does not timely receive effective treatment, PTB can lead to cavity expansion and focal fibrosis due to adverse drug reactions, bacterial variation, hepatitis B virus (HBV), human immunodeficiency virus (HIV), or diabetes. Clinically, medication remains the mainstay of treatment for patients with PTB, in which case, the curative effect, and clinical prognosis are strongly affected by the relatively long course of treatment and high drug tolerance. Diabetes is a contributory factor for impairment of the immune mechanism, hypofunction of the immune system, and an increased risk of TB infection. In addition to abnormal carbohydrate metabolism, diabetes is also associated with lipid and protein metabolism at an accelerated speed. This creates a favorable environment for the growth of *M. tb* and reduces the curative effect of anti-TB treatment for PTB patients with diabetes. Thymosins are small molecular polypeptide secreted by thymus tissue, which modulate both innate and adaptive immunity, can reverse T cell failure and restore immune reconstruction. Thymosin alpha 1 (Tα1) and thymopentin (TP-5) are two thymus-derived immunomodulatory agents. Immunomodulatory role of thymosin is established not only in microbial infections but also in malignancy, pancreatic lesions, diabetes, immunodeficiencies, and vaccine efficacy etc.

In this study, PTB patients with diabetes were treated with Tα1 injections in combination with conventional multi-modality chemotherapy to modulate the immune system, without mitigating the anti-TB effect.

**METHODS**

Ethical approval: The study was approved by the Institutional Ethics Committee of North China University of Science and Technology Affiliated Hospital on June 10, 2018 (No.: 2041ZF147), and written informed consent was obtained from all participants.

Clinical data: In this retrospective study 120 patients who were admitted to North China University of Science and Technology Affiliated Hospital between January 2017 and January 2018 due to PTB complicated with diabetes were included according to the random sampling principle, and divided into two groups by random number table method, namely the Tα1 group (n=60) and the control group (n=60).

Inclusion criteria: A patient was considered eligible for the clinical trial if he/she:

1. Was confirmed to have PTB and diabetes according to the WS 288-2008 Diagnostic criteria for pulmonary tuberculosis and the 2014 American Diabetes Association (ADA) diabetes guidelines;
2. Had not received any treatment that might affect the immune function within the past year.

Exclusion criteria: if the patient:

1. Was diagnosed with HIV infection, immune deficiency, or allergic disorders;
2. Present with serious organ dysfunction of heart, liver, or kidneys;
3. Had AIDS or cancer;
4. Was pregnant or breastfeeding;
5. Have used glucocorticoids (GCs) in the last three months. Age, sex, course of disease, cavity proportion, grade of acid-fast bacilli in sputum smear and location of lesion were comparable between the two groups. (shown in Table-I)

Therapeutic regimens:

1. The multi-modality anti-TB chemotherapy 2HRZE/4HR (H: 0.3 g isoniazid, R: 0.6 g rifampicin, Z: 1.5 g pyrazinamide, and E: 0.75 g ethambutol) was initiated and administered on alternate days, with the intensive phase containing isoniazid, rifampicin, pyrazinamide

| Group | No. of Patients | Sex | Age | Course of Disease | No. of Cavities | Involved Lung Field(s) | Sputum AFB Grades |
|-------|----------------|-----|-----|------------------|----------------|----------------------|------------------|
|       | n | Male | Female | (years) | (months) | 1-4 | ≥4 | 1+ | 2+ | 3+ | 4+ |
| Tα1 | 60 | 36  | 24  | 46.68±9.44 | 6.85±2.78 | 56 | 26 | 34 | 10 | 24 | 20 | 6 |
| Control | 60 | 40  | 20  | 47.53±9.62 | 6.77±2.12 | 54 | 22 | 38 | 12 | 18 | 22 | 8 |
| X²/t | 0.287 | 0.345 | 0.125 | 0.000 | 0.281 | 0.111 | 0.660 | 0.071 | 0.001 |
| P | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 | >0.05 |
and ethambutol, and the continuation phase with isoniazid plus rifampicin. In case sputum smears did not convert after two months of treatment, the intensive phase should be extended for another month. If necessary, chemotherapy could be extended up to nine months according to CT findings and sputum smear results. In addition to chemotherapy, the Tα1 group also received subcutaneous injections of 120 mg/d Tα1 for 12 weeks.

2. NovoMix 30 was injected subcutaneously 10 minutes before breakfast and dinner every day. The recommended starting dose was 0.2-0.3 IU/kg/d, which should be adjusted according to the results of blood glucose monitoring. For patients who responded poorly to NovoMix 30, 4 mg/d rosiglitazone was administered to improve insulin sensitivity. Target blood glucose levels are as follows: fasting blood glucose (FBG) <7.0 mmol/L, 2h postprandial blood sugar (2hPBG) <10.0 mmol/L, and bedtime blood glucose (BBG) <9.0 mmol/L.

Outcome measures:
Response evaluation criteria: Sputum smear microscopy and plain radiography of the chest were performed monthly during the treatment course. Cavity closure, lesion absorption, and sputum culture-negative conversion before and after treatment (6 and 12 months after treatment) were recorded: a. sputum culture-negative conversion: sputum culture converted to negative and was not retested positive following two months of treatment; b. lesion absorption: radiography of the chest indicated a reduction of lesion area; c. cavity closure: radiography of the chest revealed closure, obstructive closure, or shrinkage of cavities.

Measurement of lymphocytes (T-cell subsets and NK cells): Before treatment and six months after treatment, 5ml of fasting anticoagulant whole blood was collected. Peripheral blood mononuclear cells were immediately sent to the laboratory for isolation and stored at 4°C. Within 3 days, CD3+, CD4+, CD8+, CD4+/CD8+, Th17, Treg, Th17/Treg, and NK (natural killer) cells were detected by Cyto-FLEX flow cytometry. All samples were stained according to the procedure of CD45/CD8/CD4/CD3 lymphocyte test kit, then analyzed on the machine. In the operating system, template loops were set to circle total lymphocytes, T cells (CD3+/CD4+/CD8+), Th17 cells (CD3+CD4+), Treg cells (CD4+CD25+), and NK cells (CD3-CD16+CD56+) respectively. At least 5000 cells under the lymphocyte subset were obtained. The relative percentage of each T lymphocyte subset in the total lymphocytes was obtained in the software.

Sputum cytokines: Deep sputum was collected before treatment and six months after treatment. After a night of fasting, patients were asked to gargle with water and sputum aspiration was induced in a negative pressure chamber. After sputum collection, the sputum was stored at 4°C and immediately transported to the laboratory for treatment within two hour. The sputum was diluted and centrifuged to obtain the supernatant and stored at -70°C until cytokine levels were evaluated. Kits from Medgenix (Biosource International, Camarillo, Calif.) were used to determine gamma IFN-γ and TNF-α immunoreactivities. While kits from Peprotech (The United States) were used to detect IL2 and IL4.

Adverse reactions/drug toxicity: Adverse reactions such as transaminase (AST) elevation, uric acid (UA) elevation, nausea and vomiting, rash, drowsiness, and hypoglycemia were recorded during the treatment course.

Statistical analysis: Statistical analysis was performed using SPSS 22.0 software. Measurement data were expressed in the form of “mean ± standard deviation (x±s)”, and intergroup comparison was examined with the independent-samples t-test.

Table-II: Comparison of clinical efficacy [n/%].

| Group   | No. of Patients | Sputum Culture-Negative Conversion Rate | Chest Lesion Absorption Rate | Cavity Closure Rate |
|---------|----------------|----------------------------------------|----------------------------|--------------------|
|         |                | 6 months post-treatment | 12 months post-treatment | 6 months post-treatment | 12 months post-treatment | 6 months post-treatment | 12 months post-treatment |
| Tα1     | 60             | 32 (53.33) | 44 (73.33) | 36 (60.00) | 48 (80.00) | 30 (50.00) | 46 (76.67) |
| Control | 60             | 18 (30.00) | 26 (43.33) | 22 (36.67) | 30 (50.00) | 16 (26.67) | 28 (30.00) |
| χ²      | 3.360          | 5.554      | 3.270      | 5.934      | 3.455      | 5.711      |
| P       | >0.05          | <0.05      | >0.05      | <0.05      | >0.05      | <0.05      |
Quantitative data were represented by percentages (%), and intergroup comparison was examined with the χ² test. The significance level α was set at 0.05.

RESULTS

After six months of treatment, the two groups showed no statistically significant differences in sputum culture-negative conversion rate, chest lesion absorption rate, and cavity closure rate (P>0.05); following 12 months of treatment, the sputum culture-negative conversion rate, chest lesion absorption rate, and cavity closure rate in the Tα1 group increased compared with the control group, and the differences were statistically significant (P<0.05) (Table-II).

Comparison of NK and T-cell subsets: After six months of treatment, the CD3+, CD4+, CD4+/CD8+, and NK cells in the Tα1 group were remarkably higher than in the control group, whereas the CD8+, Th17, Treg, and Th17/Treg cells in the Tα1 group were substantially lower than in the control group, and the differences were statistically significant (P<0.05, respectively) (Table-III).

Comparison of sputum supernatant levels of cytokines: After six months of treatment, the sputum supernatant levels of IL-4 and TNF-α in the Tα1 group were lower than in the control group, whereas the sputum supernatant levels of IL-2 and IFN-γ in the Tα1 group were higher than in the control group, and the differences were statistically significant (P<0.05, respectively) (Table-IV).

Adverse reactions/drug toxicity: There was no statistically significant difference in the incidence rates of AST elevation, UA elevation, nausea and vomiting, rash, drowsiness, and hypoglycemia between the two groups (P>0.05) (Table-V).

DISCUSSION

Diabetes is a chronic wasting disease characterized by disorders of carbohydrate and protein metabolism, inhibition of antibody synthesis, and defects in immune function. menjadi 3. M. tb
can directly downregulate the expression of Th1 cells, and TB can lead to immune dysfunction. Diabetes is an important risk factor for secondary PTB, and TB poisoning symptoms, and anti-TB drugs can interfere with carbohydrate metabolism and lead to exacerbations of immune disorders. Poor blood sugar control can compromise anti-TB treatment. Considering that abnormal pathogenic immune response cannot be directly corrected by conventional anti-TB therapy, the key to a higher success rate of anti-TB treatment lies in improving cellular immunity. Thymosins are important immunomodulatory agents extensively used for adjuvant treatment of chronic infectious diseases. In this study, it was found that the Tα1 group outperformed the control group in sputum culture-negative conversion, lesion absorption, and cavity closure, indicating desirable clinical efficacy in treating PTB complicated with diabetes with Tα1 and multi-modality chemotherapy. This is because thymosins stimulate T-cell production by the bone marrow to improve immune function, thereby eliminating dormant or persistent bacteria in combination with anti-TB drugs. This study also revealed that the CD3+, CD4+, CD4+/CD8+ T cells, and NK-cell values in the Tα1 group were significantly higher than in the control group, whereas the CD8+, Th17, Treg, and Th17/Treg values were significantly lower than in the control group. It has been reported that Treg cells are involved in immune disorders during sepsis, and they lead to Th2 immune response, while Tα1 can down-regulate the percentage of Treg and reduce inflammatory damage. Our findings are similar. Other studies have found that Tα1 can up-regulate Treg levels in peripheral blood of patients with gastric cancer. We believe that the decrease of Treg and Th17 subgroups in the experimental group in this study may be related to the complex immune response involved in tuberculosis combined with diabetes and the differences in individual immune status. In the development and progression of PTB, it is significant to inhibit the expression of Th1 cells and increase the expression of Th2 cells. Thymosins promote differentiation and proliferation of T cells and support Th1/Th2 balance by regulating CD3+, CD4+, and CD8+ T cells, as well as the CD4+/CD8+ and Th17/Treg ratios. In addition, thymosins can improve the cytolytic and killing abilities of NK cells and enhance the phagocytic function of macrophages, thereby killing M. tb. IFN-γ is a multifunctional immunomodulator and cytokine produced by T cells upon stimulation by specific antigens. IL-2 and IFN-γ support Th1 cell proliferation and antagonize the effects of IL-4 and TNF-α. All this conforms with the findings of this study: the Tα1 group had lower sputum supernatant levels of IL-4 and TNF-α but higher sputum supernatant levels of IL-2 and IFN-γ compared with the control group. Previous studies have also shown that Tα1 can reduce liver inflammation and reduce hepatocyte apoptosis by down-regulating TNF-α and up-regulating IL-10. Adverse drug reactions occurring in the patients of the two groups during treatment mainly include an increase in AST and UA, nausea and vomiting, rash, and hypoglycemia. These symptoms are caused by anti-TB and hypoglycemic drugs and tend to be mild and reversible. No adverse reactions are produced by the Tα1 therapy.

**Limitations of this study** There are still some shortcomings in this study. The number of subjects included in this study is limited, so the conclusions drawn may not be very convincing. In addition, further studies with large-scale standard treatment are needed to verify the curative effect, safety, optimum dose, and duration of thymosin treatment.

**CONCLUSION**

Tα1 combined with multi-modality chemotherapy has a visible curative effect on PTB patients with diabetes as it can regulate immune function and reduce the levels of inflammatory cytokines. As a safe combination therapy, it seems promising for further use in clinical practice.
Li Wu et al.

Conflicts of interest: None.

Source of funding: This study is supported by Baoding Science and Technology Plan Project (No.2041ZF147).

REFERENCES

1. WHO. Global tuberculosis report 2012 [J/O]. http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf

2. Rahman MA, Sobia P, Dwivedi VP, Bhawsar A, Singh DK, Sharma P, et al. Mycobacterium tuberculosis TlyA Protein Negatively Regulates T Helper (Th) 1 and Th17 Differentiation and Promotes Tuberculosis Pathogenesis. J Biol Chem. 2015;290(23):14407-14417. doi: 10.1074/jbc.M115.653600

3. Pandey P, Pant ND, Rijal KR, Shrestha B, Kattel S, Banjara MR, et al. Diagnostic Accuracy of GeneXpert MTB/RIF Assay in Comparison to Conventional Drug Susceptibility Testing Method for the Diagnosis of Multidrug-Resistant Tuberculosis. PLoS One. 2017;12(1):e0169798. doi: 10.1371/journal.pone.0169798

4. Nelson KN, Shah NS, Mathema B, Ismail N, Brust JCM, Brown TS, et al. Spatial Patterns of Extensively Drug-Resistant Tuberculosis Transmission in KwaZulu-Natal, South Africa [published correction appears in J Infect Dis. 2019;219(5):509]. J Infect Dis. 2018;218(12):1964-1973. doi: 10.1093/infdis/jiy394

5. Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Sanzatala L, Babu S, Lichtenstein F, et al. Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Sci Rep. 2017;7(1):1999. doi: 10.1038/s41598-017-01767-4

6. Arvindalochanan V, Viswanathan V, Kumpatala S. Association of diabetes and tuberculosis—a major public health challenge. J Indian Med Assoc. 2012;110(9):646-648.

7. Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, et al. Thymosin alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020;71(6):2150-2157. doi: 10.1093/cid/ciaa630.

8. Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides. 2010;31(11):2151-8. doi: 10.1016/j.peptides.2010.09.003.

9. Ministry of Health of the People’s Republic of China. WS 288-2008 Diagnostic criteria for pulmonary tuberculosis. Beijing, People’s Medical Publishing House Co., Ltd. 2008.

10. Shen L, Pei Y, Ba JP. Interpretation of 2014 ADA diabetes guidelines. Chin J Drug Appl Monitoring. 2015;31(11):251-8. doi: 10.1093/cid/ciaa630.

11. Manns MP, Buti M, Gane E, Pavlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17066. doi: 10.1038/nrdp.2017.6

12. Shao C, Tian G, Huang Y, Liang W, Zheng H, Wei J, et al. Thymosin alpha-1 transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration. Int Immunopharmacol. 2013;13(5):646-653. doi: 10.1016/j.intimp.2012.12.051

13. Li Wu et al. 2018;15(4):3231-3238. doi: 10.3892/etm.2018.5843

14. Lai-yin Chen, Yan-hong Tian, Pei-pei Luo, Li Wu. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol. 2018;11(5):443-450. doi: 10.1016/j.ijim.2018.01.004.

15. Yang X, Qian F, He HY, Liu KJ, Lan YZ, Ni B, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro. Braz J Med Biol Res. 2012;45(1):25-32. doi: 10.1590/s0100-879x201107500159.

16. Manns MP, Buti M, Gane E, Pavlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers. 2017;3:17066. doi: 10.1038/nrdp.2017.6

17. Wang J, Shan Y, Shan H, Li G, Wang T, Guan J, et al. Thymosin alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci (Landmark Ed). 2011;16:3004-13. doi: 10.2741/3894.

18. Wang J, Shan Y, Shan H, Li G, Wang T, Guan J, et al. Thymosin alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci (Landmark Ed). 2011;16:3004-13. doi: 10.2741/3894.

19. Yang X, Qian F, He HY, Liu KJ, Lan YZ, Ni B, et al. Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro. Braz J Med Biol Res. 2012;45(1):25-32. doi: 10.1590/s0100-879x201107500159

20. Wang J, Shan Y, Shan H, Li G, Wang T, Guan J, et al. Thymosin alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci (Landmark Ed). 2011;16:3004-13. doi: 10.2741/3894.

21. Guo S, Zhao J. Immunotherapy for tuberculosis: What’s the better choice? Front Biosci (Landmark Ed). 2012;17:2684-2690. doi: 10.2741/4079.

22. Guo S, Zhao J. Immunotherapy for tuberculosis: What’s the better choice? Front Biosci (Landmark Ed). 2012;17:2684-2690. doi: 10.2741/4079.

23. King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 Treatment. Vitam Horm. 2016;102:151-178. doi: 10.1016/bs.vh.2016.04.003.

24. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E. Synergistic effect of thymosin alpha 1 and alpha beta-interferon on NK activity in tumor-bearing mice. Int J Immunopharmacol. 1989;11(5):443-450. doi: 10.1016/0192-0561(89)90172-0.

25. Link CWM, Rau CN, Udoye CC, Ragab M, Korkmaz RU, Com-dulae S, et al. IL-2-Agonist-Induced IFN-γ Exacerbates Systemic Anaphylaxis in Food Allergen-Sensitized Mice. Front Immunol. 2020;11:596772. doi: 10.3389/fimmu.2020.596772

26. Yang X, Chen Y, Zhang J, Tang T, Kong Y, Ye F, et al. Thymosin alpha1 treatment reduces hepatic inflammation and inhibits hepatocyte apoptosis in rats with acute liver failure. Exp Ther Med. 2018;15(4):3231-3238. doi: 10.3892/etm.2018.5843

Authors’ Contributions:

LW and YZ designed this study, prepared this manuscript and are responsible, accountable for the accuracy or integrity of the work.

PL and YT collected and analyzed clinical data.

LC significantly revised this manuscript.

Correspondence:

Yan-ji Zhang, Department of Infectious Diseases, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, Hebei, China.

Email: fjkpt739739517@163.com